This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best mid-cap growth stocks to buy right now. On January 14, Bank of ...
A regulatory decision on a top investigational drug won't be coming as soon as hoped.
By Siddhi Mahatole and Sahil Pandey Jan 13 (Reuters) - The U.S. Food and Drug Administration has extended its review for the expanded use of Travere Therapeutics’ drug to treat a type of rare kidney ...
The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc.
Ligand Pharmaceuticals (LGND) is a royalty investor in late-stage biopharma, with revenue and EPS growth driven by a robust ...
Lulu’s Fashion Lounge Holdings Inc (NASDAQ: LVLU) shares dipped 10.4% to $10.89 in pre-market trading. Lulu’s Fashion Lounge Holdings shares jumped 79% on Monday after Friedland Enterprises acquired a ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...
Investing.com -- Travere Therapeutics (NASDAQ:TVTX) stock tumbled 33% Tuesday after the company revealed that the U.S. Food and Drug Administration requested additional information to clarify the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results